News
EVO
3.760
-5.29%
-0.210
Warburg Research Remains a Buy on Evotec (0IRF)
TipRanks · 4d ago
Weekly Report: what happened at EVO last week (0609-0613)?
Weekly Report · 5d ago
Halozyme Therapeutics: The Waters Become Muddled
Seeking Alpha · 6d ago
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn
Seeking Alpha · 06/13 17:45
Weekly Report: what happened at EVO last week (0602-0606)?
Weekly Report · 06/09 09:07
Evotec SE Announces AGM Results and Strategic Outlook
TipRanks · 06/03 16:27
Weekly Report: what happened at EVO last week (0526-0530)?
Weekly Report · 06/02 09:07
DHT Holdings Posts Weak Sales, Joins Compass Diversified, Okta And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 05/28 12:24
Weekly Report: what happened at EVO last week (0519-0523)?
Weekly Report · 05/26 09:07
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 05/23 17:06
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/23 12:08
Weekly Report: what happened at EVO last week (0512-0516)?
Weekly Report · 05/19 09:07
Evotec price target raised to EUR 11.90 from EUR 11.60 at RBC Capital
TipRanks · 05/15 17:10
Evotec (0IRF) Gets a Buy from RBC Capital
TipRanks · 05/15 06:29
Weekly Report: what happened at EVO last week (0505-0509)?
Weekly Report · 05/12 09:07
Deutsche Bank Remains a Hold on Evotec (0IRF)
TipRanks · 05/07 13:39
Evotec AG: Strong Growth Potential and Strategic Initiatives Drive Buy Rating
TipRanks · 05/07 10:27
Evotec Secures $2.5M Grant To Generate Critical Data Supporting New TB Regimens
Benzinga · 05/07 07:13
Evotec AG Reports Q1 2025 Earnings and Strategic Progress
TipRanks · 05/07 04:23
Evotec Ag Earnings Call: Mixed Sentiment Amid Growth
TipRanks · 05/07 00:51
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.